Skip to main content
. Author manuscript; available in PMC: 2022 Aug 1.
Published in final edited form as: Trends Parasitol. 2021 May 14;37(8):709–721. doi: 10.1016/j.pt.2021.04.006

Figure 3. Multicriteria assessment of the risk of resistance and mitigation strategy.

Figure 3.

Resistance is evaluated according to the stage of advancement in the pipeline of the compound/series. Early series (A) and Late-Lead compounds (B) are down-prioritized in the event of a MIR value ≤ 6 (i.e. resistance obtained in ≤ 106 parasites), and an EC50 fold shift > 10, generated in vitro in P. falciparum Dd2 parasites subjected to a selection pressure of 3×EC90. Additionally, Late-Leads showing a cross-resistance greater than a 5-fold EC50 shift compared with marketed antimalarials or advanced MMV portfolio compounds, or a median EC50 with P. falciparum isolates 5-fold higher compared with values obtained with sensitive laboratory strains, will be down-prioritized.